Biomarin Pharmaceutical Inc
(NAS:BMRN)
$
66.24
0.11 (0.17%)
Market Cap: 12.62 Bil
Enterprise Value: 12.28 Bil
PE Ratio: 39.66
PB Ratio: 2.33
GF Score: 67/100 Biomarin Pharmaceutical Inc at Bank of America Merrill Lynch Napa Healthcare Conference (Virtual) Transcript
Jun 24, 2020 / 03:30PM GMT
Release Date Price:
$120.63
(-0.90%)
Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst
Okay. Welcome to the third day of the BofA Virtual Napa Conference. We all would much rather be in actual Napa versus virtual Napa, but that's okay. We are excited -- my name is Geoff Meacham. I'm the senior biopharma analyst here, and I have Aspen Mori from my team as well on the line. We're really excited to have BioMarin with us for this session. And speaking on behalf of BioMarin, we have Hank Fuchs, who's President of Worldwide R&D; as well as Brian Mueller, acting CFO. Guys, are you there?
Henry J. Fuchs
BioMarin Pharmaceutical Inc. - President of Worldwide Research & Development
Yes. Good morning, Geoff.
Brian R. Mueller
BioMarin Pharmaceutical Inc. - Executive VP & CFO
We are. Yes. Good morning, everyone. Thank you, Geoff.
Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst
Good morning. Great. Yes. So the format is, I'm going to
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot